NHI should cover Revlimid under risk-sharing agreements
Published: 2013-05-15 06:56:00
Updated: 2013-05-15 06:56:00
Celgene Korea was in negotiations to agree a deal to make its cancer drug Revlimid more affordable to the National Health Insurance (NHI) last year, but failed to reverse a negative decision of the National Health Insurance Corporation.
The company is one of the first to take up the opportunit...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
